Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur, the vaccines division of Sanofi Aventis, has received the new seed virus to start the production process for Swine Flu vaccine (H1N1). Sanofi can start industrial production as soon as it gets approval from public health agencies, following quality control measures.
Subscribe to our email newsletter
Sanofi will initiate the development process called passaging, which will yield a working seed for the vaccine. Passaging is the process to acclimate virus to grow in a production environment at optimum yield. This process is expected to take approximately two weeks, said the company.
Wayne Pisano, President and CEO, Sanofi Pasteur, said: “Sanofi Pasteur looks forward to quickly understanding how this virus performs in a vaccine manufacturing environment and developing a working seed that will enable large-scale production. This is an important step for engaging Sanofi Pasteur’s resources and expertise to support public health authorities and the directives they provide us.